JOSEPH GRILLO, MD

OKLAHOMA CITY, OK

Research Active
Orthopaedic Surgery - Foot and Ankle Surgery NPI registered 21+ years 31 publications 1948 – 2026 NPI: 1598761736
MiceRadiographyCell Line, TumorComputer SimulationDrug ApprovalNeovascularization, PathologicModels, BiologicalCopperAutopsyUnited States Food and Drug AdministrationAngiogenesis InhibitorsCaulobacter crescentusThrombospondin 1PharmacokineticsPharmacology, Clinical

Practice Location

1044 S.W. 44TH ST.
OKLAHOMA CITY, OK 73109

Phone: (405) 631-4263

What does JOSEPH GRILLO research?

Dr. Grillo studies multiple health issues, particularly emphasizing pediatric sleep disorders, severe allergies, and the resilience of bacterial infections. He looks at how at-home sleep studies can help families detect issues like obstructive sleep apnea in children more efficiently than hospital tests. Additionally, he investigates new treatments for severe allergic reactions, such as a novel nasal spray for faster relief. His research also dives into how certain bacteria adapt to toxic environments, which is crucial for developing better antibiotics. Dr. Grillo's work extends to understanding cancer treatments, exploring how certain drugs can extend patient lives and improve responses in leukemia and myelofibrosis cases.

Key findings

  • Home sleep studies can help diagnose obstructive sleep apnea in children, but pulse oximetry often misses cases, leading to potential treatment delays.
  • In a case series, 92% of patients treated with neffy nasal spray after allergic reactions remained in treatment for 30 days, showing its effectiveness over traditional injections.
  • A study showed that 43% of patients starting buprenorphine treatment through ketamine assistance successfully transitioned to ongoing therapy, indicating a reduced withdrawal symptom experience.
  • Patients treated with a combination of obinutuzumab and chlorambucil for chronic lymphocytic leukemia lived longer without disease worsening (23 months) compared to 11 months for those on chlorambucil alone.
  • 42% of patients treated with ruxolitinib for myelofibrosis saw significant reductions in spleen size, improving symptoms compared to only 1% with a placebo.

Frequently asked questions

Does Dr. Grillo study sleep disorders?
Yes, Dr. Grillo focuses on diagnosing and managing sleep disorders in children, particularly through home sleep studies.
What treatments has Dr. Grillo researched for allergies?
He has investigated a new nasal spray that delivers epinephrine, providing a faster treatment option for severe allergic reactions.
Is Dr. Grillo's work relevant to cancer patients?
Yes, his research on new treatments for chronic lymphocytic leukemia and myelofibrosis offers hope for patients who have limited treatment options.
Can Dr. Grillo's research help with bacterial infections?
Absolutely, his studies on bacterial resilience contribute to our understanding of how to combat antibiotic resistance.
How does Dr. Grillo's work affect treatment for opioid use disorder?
His research on using ketamine to assist in starting buprenorphine treatment may ease the transition for patients struggling with opioid dependence.

Publications in plain English

Sweet dreams at home: A review of paediatric domiciliary sleep studies.

2026

Sleep medicine

Grillo J, Eckert DJ, Shivji S, Hei Dong IS, Catcheside PG +1 more

Plain English
This review looked at how sleep studies done at home (rather than in a hospital) could help diagnose sleep problems in children. It found that while home sleep tests are generally more convenient and preferred by parents, methods like pulse oximetry often miss diagnosing obstructive sleep apnea accurately. Improving these home tests could lead to faster and better treatment for kids with sleep issues, especially those living far from medical centers. Who this helps: This helps children with sleep disorders and their families.

PubMed

BR-Bodies Facilitate Adaptive Responses and Survival During Copper Stress in.

2025

bioRxiv : the preprint server for biology

Passos C, Tomares D, Yassine H, Schnorr W, Hunter H +8 more

Plain English
This study looked at how bacteria respond to stress from copper, a toxic heavy metal. Researchers found that certain cellular structures in bacteria, called BR-bodies, help them survive by changing their form and creating a protective environment that keeps their important enzymes working properly. Specifically, the study showed how interactions between copper and BR-bodies make them more solid, helping the bacteria adapt and survive under copper stress. Who this helps: This helps patients by improving our understanding of bacterial resistance to antibiotics, which could lead to better treatments for infections.

PubMed

BR-bodies facilitate adaptive responses and survival during copper stress in Caulobacter crescentus.

2025

The Journal of biological chemistry

Passos C, Tomares DT, Yassine H, Schnorr WE, Hunter H +8 more

Plain English
This study looked at how a type of structure in bacteria, called BR-bodies, helps the bacterium Caulobacter crescentus survive high levels of copper, which is toxic. The researchers discovered that specific interactions between copper and a protein in these BR-bodies improve the bacteria’s resilience, allowing them to function better under stress. They found that this mechanism is important because it helps maintain the health of the bacteria when they encounter harmful metals. Who this helps: This benefits researchers studying microbial resilience in harmful environmental conditions.

PubMed

First reported allergen immunotherapy anaphylaxis treated with neffy nasal spray: A case series.

2025

The journal of allergy and clinical immunology. Global

Rosenblum J, Puglisi G, Grillo J

Plain English
This study looked at how well the neffy nasal spray, a new way to deliver epinephrine, works for treating severe allergic reactions (anaphylaxis) in patients undergoing allergen immunotherapy. The researchers found that patients who had allergic reactions in the clinic felt better quickly after using the neffy spray, showing it could be a good option instead of traditional injections. This is significant because it offers a faster, easier treatment method for critical allergic episodes. Who this helps: This benefits patients with severe allergies who undergo allergen immunotherapy.

PubMed

Ketamine-assisted buprenorphine initiation: a pilot case series.

2024

Addiction science & clinical practice

Grande LA, Hutch T, Jack K, Mironov W, Iwuoha J +4 more

Plain English
This study looked at how using low doses of ketamine can help people with opioid use disorder start buprenorphine treatment more easily. Out of 37 patients who tried the ketamine, 16 (about 43%) successfully started buprenorphine, and among those who reported using the ketamine, 11 out of 12 (92%) stayed in treatment for 30 days. This is important because it suggests that ketamine can reduce withdrawal symptoms and help more people begin effective treatment for their opioid dependence. Who this helps: This benefits patients struggling with opioid use disorder who are hesitant to start buprenorphine treatment.

PubMed

AIR SAC TREMATODES (CYCLOCOELIDAE STOSSICH, 1902) INFECTING BIRDS IN ZOOLOGICAL INSTITUTIONS IN THE UNITED STATES.

2023

Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians

Greiner EC, Zimmerman DM, Delaski KM, Dronen NO, Hammond EE +8 more

Plain English
This study looked at air sac trematodes, a type of parasite, affecting 23 bird species in various zoos across the U.S. It found that 47% of a certain nonnative snail species collected from these aviaries carried larvae that matched adult trematodes found in the infected birds. This is important because it highlights risks associated with moving birds between facilities, which could spread these infections. Who this helps: This helps zoos and aviaries manage bird health better by understanding how these parasites spread.

PubMed

Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary.

2021

CPT: pharmacometrics & systems pharmacology

Jean D, Naik K, Milligan L, Hall S, Mei Huang S +16 more

PubMed

Long-term durability of a physician-modified endovascular graft.

2020

Journal of vascular surgery

Hurd JR, Tatum B, Grillo J, Arthurs Z, Singh N +4 more

Plain English
In this study, researchers evaluated a special type of graft used for blood vessel repairs seven years after it was implanted. They found only one small issue—a strut fracture—while the graft itself remained undamaged and aligned properly. This is significant because it shows that these modified grafts can hold up well over time, which is important for patients who need long-lasting solutions for their vascular issues. Who this helps: This helps patients requiring vascular surgeries and their doctors.

PubMed

Robert M. Nerem - International expert on mechanobiology, cellular engineering, tissue engineering and regenerative medicine.

2020

Regenerative therapy

García AJ, Grillo J

PubMed

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.

2019

Journal of pharmaceutical sciences

Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM +2 more

Plain English
This paper discusses how the U.S. Food and Drug Administration (FDA) is using a method called physiologically based pharmacokinetic modeling to better understand how drugs move through the body. The authors point out that while this modeling can improve decision-making for drug approval, there are still gaps in knowledge and challenges in implementing this approach effectively. This matters because improving drug assessment can lead to safer and more effective treatments for patients. Who this helps: This helps drug developers and regulatory officials, ultimately benefiting patients.

PubMed

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.

2015

CPT: pharmacometrics & systems pharmacology

Wagner C, Zhao P, Pan Y, Hsu V, Grillo J +2 more

Plain English
Researchers at the FDA held a workshop to discuss how a special modeling technique called PBPK can help determine the right dose of medication during drug development. The workshop included experts who shared their thoughts on how PBPK works, its reliability, and how it can be used in regulatory processes. This is important because better dose selection can lead to safer and more effective medications for patients. Who this helps: This helps patients and healthcare providers by ensuring medications are dosed accurately.

PubMed

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

2014

The oncologist

Alvandi F, Kwitkowski VE, Ko CW, Rothmann MD, Ricci S +11 more

Plain English
This study looked at a new treatment called omacetaxine mepesuccinate for adults with chronic myeloid leukemia (CML) who haven't responded well to other therapies. The FDA found that 18% of patients in the early stage of CML saw significant improvements in their condition, lasting an average of 12.5 months, while 14% of patients in a more advanced stage had a similar success, lasting around 4.7 months. This matters because it offers hope for patients who have few options left after failing other treatments. Who this helps: This helps patients with chronic myeloid leukemia who haven't responded to at least two other treatments.

PubMed

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.

2014

Clinical cancer research : an official journal of the American Association for Cancer Research

Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P +14 more

Plain English
The study looked at the effectiveness of a new treatment, obinutuzumab combined with chlorambucil, for patients with previously untreated chronic lymphocytic leukemia (CLL). Results showed that patients receiving this combination treatment lived longer without their disease worsening, with an average of 23 months compared to 11 months for those taking chlorambucil alone. Additionally, 75.9% of patients in the combination group responded positively to treatment, compared to just 32.1% in the chlorambucil-only group. Who this helps: This helps patients diagnosed with chronic lymphocytic leukemia.

PubMed

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

2012

Clinical cancer research : an official journal of the American Association for Cancer Research

Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H +11 more

Plain English
This study looked at the effectiveness of a drug called ruxolitinib for patients with serious forms of myelofibrosis, a type of bone marrow cancer. The results showed that 42% of patients treated with ruxolitinib had a significant reduction in spleen size compared to just 1% with a placebo, and 46% of patients saw a substantial improvement in their symptoms compared to only 5% with the placebo. This is important because it means ruxolitinib is a new treatment option that can help manage the painful symptoms and complications of myelofibrosis. Who this helps: Patients with intermediate and high-risk myelofibrosis.

PubMed

Regulation of the angiogenesis inhibitor thrombospondin-1 by the breast cancer susceptibility gene-1 (BRCA1).

2011

The breast journal

Grillo J, DelloRusso C, Lynch RC, Folkman J, Zaslavsky A

PubMed

Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

2010

Blood

Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J +3 more

Plain English
Researchers studied how a protein called thrombospondin-1, which helps prevent new blood vessel growth (a process called angiogenesis) in tumors, is affected in mice with cancer. They found that tumor-bearing mice had higher levels of thrombospondin-1 in their platelets due to more of this protein being made in their blood cells, which helps slow down the growth of tumors by blocking blood vessel formation. This finding shows that monitoring thrombospondin-1 in platelets might help doctors understand how tumors are responding to treatment. Who this helps: Patients with cancer.

PubMed

Regional control of tumor growth.

2010

Molecular cancer research : MCR

Zaslavsky A, Chen C, Grillo J, Baek KH, Holmgren L +3 more

Plain English
This study examined how tumors grow differently depending on their location in the abdominal cavity of mice. It found that tumors near the upper abdomen grow faster than those in the lower abdomen, with a fourfold increase in growth rate in the upper area. This happens because of a substance called thrombospondin-1 that limits blood vessel growth in the lower abdomen, and modifying this can impact tumor growth in humans with similar conditions. Who this helps: This helps patients with abdominal cancers, especially those facing tumor growth in different areas of the abdomen.

PubMed

Personal accounts: Jack and the clubhouse road to recovery.

2009

Psychiatric services (Washington, D.C.)

Grillo J

PubMed

Oxygen permeation and microbial ingress through a film-coated and uncoated elastomeric closure in A glass vial: a comparative study.

2004

PDA journal of pharmaceutical science and technology

Andress M, Dull H, Gurley T, Remo E, Grillo J +2 more

Plain English
This study compared two types of closures for drug vials: one made of elastic material and one that had a thin protective film covering it. The researchers found that the film coating did not affect the amount of oxygen or germs that could enter the vial, meaning both types of closures work equally well in keeping the contents safe. This is important because it shows that using the film coating doesn't provide any extra benefits for the protection of medications. Who this helps: This helps patients and healthcare providers by ensuring that both types of vial closures are effective.

PubMed

One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women.

2001

The Journal of clinical endocrinology and metabolism

Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M +7 more

Plain English
This study looked at whether a year of treatment with a hormone called insulin-like growth factor I (IGF-I) could improve bone density, body composition, or psychological health in healthy postmenopausal women over 60 years old. The results showed that, even though IGF-I levels increased significantly after treatment, there were no changes in bone density, body composition, or any psychological measures, meaning the hormone did not make a positive impact. This matters because it suggests that IGF-I therapy is not effective for improving health in this age group. Who this helps: This helps doctors understand the limitations of IGF-I treatment for older women.

PubMed

[Cor triatriatum associated with Wolff-Parkinson-White syndrome].

2001

Revista espanola de cardiologia

Wangüemert F, Medina A, Ortega JR, Caballero E, Martínez E +1 more

Plain English
This study looked at a 34-year-old woman who experienced racing heartbeats due to Wolff-Parkinson-White syndrome, a condition that can cause rapid heart rhythms. The research found that she also had a heart abnormality called cor triatriatum, which was identified using an ultrasound of the heart. This discovery is important because it shows that doctors need to be aware of this rare heart defect in patients with Wolff-Parkinson-White syndrome, as it may impact treatment options. Who this helps: This helps doctors and patients with similar heart conditions.

PubMed

Angiographic anatomy of the inferior right atrial isthmus in patients with and without history of common atrial flutter.

1999

Circulation

Cabrera JA, Sanchez-Quintana D, Ho SY, Medina A, Wanguemert F +4 more

Plain English
This study examined the lower part of the right atrium, called the inferior right atrial isthmus, in patients with and without common atrial flutter, which is a type of heart rhythm problem. Researchers found that the isthmus was larger in patients with atrial flutter (about 37 mm long) compared to those without it (around 28 mm long). This is important because understanding the differences in heart structure can help doctors improve treatment for patients with this condition. Who this helps: This helps patients with atrial flutter and their doctors by providing insights for better treatment strategies.

PubMed

The relationship between selected causes of postneonatal infant mortality and particulate air pollution in the United States.

1997

Environmental health perspectives

Woodruff TJ, Grillo J, Schoendorf KC

Plain English
This study looked at how air pollution, specifically tiny particles (PM10), affects infant deaths in the U.S. By analyzing data from around 4 million babies born between 1989 and 1991, researchers found that babies exposed to high levels of PM10 had a higher postneonatal death rate of 3.7 per 1,000 live births, compared to 3.1 for those with low exposure. This matters because it shows that cleaner air could lead to fewer infant deaths, especially from respiratory issues and sudden infant death syndrome. Who this helps: This helps infants and their families by promoting better air quality to ensure healthier lives.

PubMed

Raising doubts about claims of malingering: implications of relationships between MCMI-II and MMPI-2 performances.

1994

Journal of clinical psychology

Grillo J, Brown RS, Hilsabeck R, Price JR, Lees-Haley PR

Plain English
This study looked at test results from 90 people making personal injury claims to see how personality disorders relate to how accurately they respond to psychological tests. Most personality disorders, except for Dependent and Narcissistic, showed a strong link to responses indicating that individuals might be exaggerating their symptoms. This matters because it suggests that personality disorders, rather than simply faking bad, may be behind these exaggerated claims in legal settings. Who this helps: This helps doctors and legal professionals better understand and evaluate personal injury claims.

PubMed

Silicone implant arthroplasty: a retrospective analysis.

1993

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons

Hetherington VJ, Mercado C, Karloc L, Grillo J

Plain English
This study looked at 19 silicone implants used in the big toe joint of 15 patients, following them for about 6 years. Researchers found that many patients experienced pain and limited movement after the surgery, with only 6 out of 16 able to grip with their toes properly. Despite these issues, most patients reported being satisfied with the results, indicating a need for more extensive research to better understand the complications related to these implants. Who this helps: This helps patients needing big toe joint replacement, as well as doctors evaluating treatment options.

PubMed

Spotlight on rehabilitation.

1991

Hospital materiel management quarterly

Brodsky H, Frumenti J, Grillo J

Plain English
This study looks at how important it is for healthcare facilities to choose the right equipment for rehabilitation programs based on patients' needs, not just costs. It highlights that directors in charge of purchasing must understand how equipment impacts patient safety and recovery. This matters because using the correct tools can significantly improve patient outcomes and ensure better overall care. Who this helps: This benefits patients undergoing rehabilitation and the healthcare professionals involved in their care.

PubMed

Survival after bilateral congenital diaphragmatic hernia.

1990

Clinical pediatrics

Sokal MM, Yellin PB, Mestel AL, Grillo J

PubMed

[Mitral valvoplasty with a balloon catheter: initial experience with a new technic].

1987

Arquivos brasileiros de cardiologia

Mossmann RA, Blacher C, Koehler N, Guaragna JC, Sukienik B +5 more

PubMed

Adjuvant chemotherapy in the treatment of advanced tumors of the head and neck.

1980

American journal of surgery

Spaulding MB, Klotch D, Grillo J, Sanani S, Loré JM

Plain English
This study looked at a new treatment method for patients with advanced head and neck tumors who had a low chance of successful surgery alone. Twenty-eight patients received two rounds of chemotherapy before surgery, and the results were promising: three patients showed no signs of cancer in their removed tumors, and most had very few side effects. Overall, 25 patients had surgery, and the majority remained cancer-free for up to 18 months after the treatment, which is significant because it shows that adding chemotherapy can improve outcomes for patients facing serious cancer. Who this helps: This helps patients with advanced head and neck cancers.

PubMed

[About the effects of streptomycin on leprosy].

1948

Zeitschrift fur Hygiene und Infektionskrankheiten; medizinische Mikrobiologie, Immunologie und Virologie

GRILLO J

PubMed

[About the chemotherapy of mycobacillosis].

1948

Anales. Sociedad de Biologia de Bogota

GRILLO J, KRAKAUER E

PubMed

Frequent Co-Authors

Haleh Saber Julie Bullock Edvardas Kaminskas Richard Pazdur Judah Folkman Alexander Zaslavsky Christie Passos Hadi Yassine Hannah Hunter Helena K Wolfe-Feichter

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.